For example, both this study on GP6 and previous research on CIP suggest that GP6 treatment would effectively target bacterial pathogens with acquired CIP resistance, whereas the reverse is not the case. This evidence concerns the gene GP6 and hereditary sensory and autonomic neuropathy.